SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Gonzalez-Martin AJ, Calvo E, Bover I, et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol. 2005; 16: 749-755.
  • 2
    Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003; 61: 2099-2106.
  • 3
    Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006; 24: 4699-4707.
  • 4
    Alvarez Secord A, Berchuck A, Higgins R, et al. A multicenter, randomized, phase II study evaluating the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer [abstract]. Gynecol Oncol. 2010; 116( suppl): A3.
  • 5
    Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005; 8: 521-533.
  • 6
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 7
    Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570-579.
  • 8
    Dobrez D, Cella D, Pickard AS, et al. Estimation of patient preference-based utility weights from the Functional Assessment of Cancer Therapy-General. Value Health. 2007; 10: 266-272.
  • 9
    Havrilesky LJ, Secord AA, Kulasingam S, Myers E. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol. 2007; 107: 211-218.
  • 10
    Pfisterer J, Ledermann JA. Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol. 2006; 33: S12-S16.
  • 11
    Rocconi RP, Case AS, Straughn JM Jr, Estes JM, Partridge EE. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis. Cancer. 2006; 107: 536-543.
  • 12
    Le QA, Hay JW. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer. 2009; 115: 489-498.
  • 13
    Miyazaki Y, Harada T, Akase T, Arakawa I, Inoue T. Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan. Clin Ther. 2009; 31( pt 2): 2433-2444.
  • 14
    Gold M, Siegel J, Russell L, Weinstein M, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.